Search results for "malattie"

showing 10 items of 1963 documents

Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity…

2021

Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) in a clinical practice setting. Study design EAGLE was a retrospective, 2-year, cohort observational, multicenter study conducted in Italy that analyzed secondary data of treatment-naïve patients with nAMD. The primary endpoint evaluated the mean annualized number of anti-VEGF injections at Years 1 and 2. The main secondary endpoints analyzed the mean change in visual acuity (VA) from baseline and variables associated with visual outcomes at Years 1 and 2. Results Of the 752 patients enrolled, 745 (99.07…

MaleEaglesAntiVEGF Drugs nAMD clinical practiceVisual AcuitySocial SciencesRetinal NeovascularizationInfographicsGeographical locationsMacular DegenerationMedical ConditionsEndocrinologyRetrospective StudieClinical endpoint80 and overPsychologyAged 80 and overEukaryotaItalyCohortMedicineHumanmedicine.medical_specialtyScienceDrug Administration ScheduleFollow-Up StudieSigns and Symptomsbiology.animalLinear regressionHumansAgedRetrospective StudiesSettore MED/30 - Malattie Apparato VisivoData VisualizationOrganismsBiology and Life Sciencesmedicine.diseaseOphthalmologyMacular DisordersLesionsEyesObservational studyClinical MedicinePeople and placesNeuroscienceVascular Endothelial Growth Factor AVisual acuityTime FactorsEye DiseasesVisionPhysiologyAngiogenesis InhibitorsMedicine and Health SciencesGeriatric OphthalmologyData ManagementMultidisciplinarybiologyQRetinal DegenerationRChartsEuropeAged; Aged 80 and over; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Intravitreal Injections; Italy; Macular Degeneration; Male; Retinal Neovascularization; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual AcuityTreatment OutcomeVertebratesIntravitreal InjectionsRetinal DisordersSensory PerceptionFemalemedicine.symptomAnatomyAngiogenesis InhibitorResearch ArticleEagleComputer and Information SciencesTime FactorBirdsOcular SystemInternal medicineSettore MED/30Growth FactorsmedicineAnimalsEuropean UnionRaptorsEndocrine Physiologybusiness.industryIntravitreal InjectionCognitive PsychologyRetrospective cohort studyMacular degenerationGeriatricsAmniotesCognitive SciencePerceptionbusinessZoologyHeadFollow-Up Studies
researchProduct

Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings f…

2020

Background and aims There is poor knowledge on characteristics, comorbidities and laboratory measures associated with risk for adverse outcomes and in-hospital mortality in European Countries. We aimed at identifying baseline characteristics predisposing COVID-19 patients to in-hospital death. Methods and results Retrospective observational study on 3894 patients with SARS-CoV-2 infection hospitalized from February 19th to May 23rd, 2020 and recruited in 30 clinical centres distributed throughout Italy. Machine learning (random forest)-based and Cox survival analysis. 61.7% of participants were men (median age 67 years), followed up for a median of 13 days. In-hospital mortality exhibited a…

MaleEpidemiologyEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologycomputer.software_genreMachine Learning0302 clinical medicineRetrospective StudieRisk FactorsCardiovascular DiseaseEpidemiology80 and overMedicineAge FactorViralHospital MortalityBetacoronavirus Hospital MortalityYoung adultAged 80 and overNutrition and DieteticsCOVID-19; Epidemiology; In-hospital mortality; Risk factorsMortality rateHazard ratioAge FactorsMiddle AgedIn-hospital mortalityC-Reactive ProteinCardiovascular DiseasesFemaleSurvival AnalysiCardiology and Cardiovascular MedicineCoronavirus InfectionsHumanGlomerular Filtration RateAdultmedicine.medical_specialtyAdolescentPneumonia Viral030209 endocrinology & metabolismSettore MED/17 - MALATTIE INFETTIVEMachine learningCOVID-19; Epidemiology; In-hospital mortality; Risk factors; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; C-Reactive Protein; COVID-19; Cardiovascular Diseases; Coronavirus Infections; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Pandemics; Pneumonia Viral; Retrospective Studies; Risk Factors; SARS-CoV-2; Survival Analysis; Young Adult; Betacoronavirus; Hospital Mortality; Machine LearningArticle03 medical and health sciencesBetacoronavirusYoung AdultHumansRisk factorPandemicsSurvival analysisAgedRetrospective StudiesPandemicBetacoronavirubusiness.industryCoronavirus InfectionSARS-CoV-2Risk FactorCOVID-19Retrospective cohort studyPneumoniaSurvival AnalysisConfidence intervalRisk factorsArtificial intelligencebusinesscomputerNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Long-term efficacy of botulinum toxin A for treatment of blepharospasm,hemifacial spasm, and spastic entropion: a multicentre study using two drug-do…

2009

PURPOSE: To investigate the long-term effectiveness and safety of botulinum neurotoxin A (BoNT-A) treatment in patients with blepharospasm (BEB), hemifacial spasm (HFS), and entropion (EN) and to use for the first time two modified indexes, 'botulin toxin escalation index-U' (BEI-U) and 'botulin toxin escalation index percentage' (BEI-%), in the dose-escalation evaluation. METHODS: All patients in this multicentre study were followed for at least 10 years and main outcomes were clinical efficacy, duration of relief, BEI-U and BEI-%, and frequency of adverse events. RESULTS: BEB, HFS, and EN patients received a mean BoNT-A dose with a significant inter-group difference (P<0.0005, respectivel…

MaleEye diseaseEcchymosisBlepharospasmBlepharospasmBlepharospasm Hemifacial spasmPtosismedicineHumansHemifacial SpasmLongitudinal StudiesBotulinum Toxins Type AAdverse effectAgedDiplopiaAged 80 and overDose-Response Relationship Drugbusiness.industrySettore MED/30 - Malattie Apparato VisivoEntropionMiddle Agedmedicine.diseasebotulinum toxin A; Blepharospasm Hemifacial spasm; entropion; drug-dose escalation indexdrug-dose escalation indexEntropionOphthalmologyDrug CombinationsNeuromuscular AgentsMuscle SpasticityAnesthesiaFemalemedicine.symptombotulinum toxin AbusinessHemifacial spasmFollow-Up Studies
researchProduct

Do we really need new medical information about the Turin Shroud?

2014

Abstract Image processing of the Turin Shroud (TS) shows that the Man represented in it has undergone an under glenoidal dislocation of the humerus on the right side and lowering of the shoulder, and has a flattened hand and enophthalmos; conditions that have not been described before, despite several studies on the subject. These injuries indicate that the Man suffered a violent blunt trauma to the neck, chest and shoulder from behind, causing neuromuscular damage and lesions of the entire brachial plexus. The posture of the left claw-hand is indicative of an injury of the lower brachial plexus, as is the crossing of the hands on the pubis, not above the pubis as it would normally be, and …

MaleForensic pathologymedicine.medical_specialtyThoracic InjuriesFamous PersonsContusionsPoison controlWounds PenetratingViolenceWounds NonpenetratingChristianityFractures BoneBluntmedicineSettore MED/33 - Malattie Apparato LocomotoreHumansBrachial PlexusHumerusForensic PathologyHistory AncientGeneral Environmental ScienceHemothoraxbusiness.industryEnophthalmosLung InjuryHemothoraxmedicine.diseaseTurin Shroud Trauma to the shoulder neck and chest Humerus dislocation Enophthalmos HemothoraxSurgerybody regionsmedicine.anatomical_structureLiteratureBlunt traumaForensic AnthropologyWounds and InjuriesGeneral Earth and Planetary SciencesShoulder Injuriesmedicine.symptomHomicidebusinessBrachial plexus
researchProduct

Next-generation sequencing confirms the implication of SLC24A1 in autosomal-recessive congenital stationary night blindness.

2015

Congenital stationary night blindness (CSNB) is a clinically and genetically heterogeneous retinal disorder which represents rod photoreceptor dysfunction or signal transmission defect from photoreceptors to adjacent bipolar cells. Patients displaying photoreceptor dysfunction show a Riggs-electroretinogram (ERG) while patients with a signal transmission defect show a Schubert-Bornschein ERG. The latter group is subdivided into complete or incomplete (ic) CSNB. Only few CSNB cases with Riggs-ERG and only one family with a disease-causing variant in SLC24A1 have been reported. Whole-exome sequencing (WES) in a previously diagnosed icCSNB patient identified a homozygous nonsense variant in SL…

MaleGenes RecessiveSodium-Calcium ExchangerNight BlindnessElectroretinographyMyopiaHumansExomeGenetic Predisposition to DiseaseAmino Acid SequenceSLC24A1Family HealthHigh-throughput sequencingBase SequenceSequence Homology Amino AcidSettore MED/30 - Malattie Apparato VisivoHomozygoteHigh-Throughput Nucleotide SequencingEye Diseases HereditaryGenetic Diseases X-LinkedPedigreeNight BlindneMutationFemaleCongenital stationary night blindneHumanClinical genetics
researchProduct

Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Stu…

2018

Introduction. The management of bisphosphonate-related osteonecrosis of the jaw (BRONJ), with no evidence-based guidelines, remains controversial. We aimed to evaluate the efficiency of a conservative surgical treatment combining Er,Cr:YSGG laser and platelet-rich plasma (PRP) for the treatment of BRONJ in cancer patients. Methods. We performed a longitudinal cohort study. Inclusion criteria were (1) age ≥ 18 years; (2) cancer diagnosis; (3) treatment with NBP because of the underlying cancer. Results. We consecutively recruited ten patients diagnosed with BRONJ in stage I or II. These patients underwent a surgical laser-assisted therapy together with autologous PRP. At the latest follow-up…

MaleGenetics and Molecular Biology (all)medicine.medical_specialtyLongitudinal studyArticle SubjectImmunology and Microbiology (all)medicine.medical_treatmentSettore MED/19 - Chirurgia Plasticalcsh:MedicineLasers Solid-StateSettore MED/08 - Anatomia PatologicaBiochemistryGeneral Biochemistry Genetics and Molecular BiologySettore MED/01 - Statistica Medica03 medical and health sciences0302 clinical medicineSettore MED/28 - Malattie OdontostomatologichemedicineHumansLongitudinal StudiesProspective StudiesSurgical treatmentProspective cohort studyAgedAged 80 and overSurgical approachBiochemistry Genetics and Molecular Biology (all)Bone Density Conservation AgentsDiphosphonatesGeneral Immunology and MicrobiologyPlatelet-Rich Plasmabusiness.industrylcsh:RCancer030206 dentistryGeneral MedicineBisphosphonatemedicine.diseaseSurgery030220 oncology & carcinogenesisPlatelet-rich plasmaClinical StudyBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusinessBiochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)
researchProduct

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

2011

An investigation was undertaken to determine whether specific pol mutations hinder long-term immune recovery regardless of virological response. In total, 826 patients with >50 HIV RNA copies/ml, who underwent genotypic resistance testing between 1 January 2000 and 31 December 2003 after >3 years of antiretroviral treatment, and were followed up for >3 years after genotypic resistance testing, were analyzed retrospectively. The outcome of the study was the lack of immune recovery after >3 years of follow-up, defined as a slope by linear regression 50 copies/ml divided by the number of HIV RNA measurements during follow-up. Logistic regression was used for univariable and multivariable analy…

MaleHIV InfectionsDrug resistanceLogistic regressionResistance to nucleoside reverse transcriptase inhibitorCD4+ T-lymphocyteRetrospective StudieImmunopathologyAntiretroviral Therapy Highly ActiveResistance to non-nucleoside reverse transcriptase inhibitorgeneticsResistance to protease inhibitorHIV Infectionresistance to nucleoside reverse transcriptase inhibitorsViralSidaresistance to protease inhibitorsbiologyReverse-transcriptase inhibitorViral LoadGenes poldrug therapy/immunology/virologyReverse Transcriptase InhibitorInfectious DiseasesTreatment Outcomeresistance to non-nucleoside reverse transcriptase inhibitorsReverse Transcriptase InhibitorsFemaleViral loadmedicine.drugHumanpolAnti-HIV AgentsAntiretroviral TherapyViremiaInfectious DiseaseSettore MED/17 - MALATTIE INFETTIVEpharmacology/therapeutic useAcquired immunodeficiency syndrome (AIDS)VirologyDrug Resistance ViralmedicineHumansHighly ActiveRetrospective StudiesAnti-HIV Agents; pharmacology/therapeutic use Antiretroviral Therapy; Highly Active CD4 Lymphocyte Count Drug Resistance; Viral; genetics Female Genes; pol HIV Infections; drug therapy/immunology/virology HIV-1; drug effects/enzymology/genetics Humans Male Mutation Retrospective Studies Reverse Transcriptase Inhibitors; therapeutic use Treatment Outcome Viral Loaddrug resistanceAnti-HIV Agentbiology.organism_classificationmedicine.diseaseVirologyCD4 Lymphocyte CountGenesdrug effects/enzymology/geneticstherapeutic useMutationCD4+ T-lymphocytesHIV-1
researchProduct

Hormonal, auxological and clinical follow-up in children with connatal HIV infection: personal records

2006

Auxological and endocrinological complications frequently occur in children with connatal HIV infection. These complications seem to be related both to the infection itself and the antiretroviral therapy. Many children consequently show height-weight and pubertal retardation without any evidence of hormonal deficit. We studied 10 children with connatal HIV infection who were enrolled in this analysis and followed up for 7 years in order to evaluate their height-weight growth, pubertal maturation, bone age progression and hormonal pattern [basal Growth hormone (GH) and GH after Clonidine or Insulin stimulation, Insulin-like Growth Factor 1 (IGF-1), Insulin-like Growth Factor Binding Protein …

MaleHIV hormonal follow-up auxological follow-up clinical follow-upSettore MED/17 - Malattie InfettiveBody WeightInfant NewbornInfantHIV InfectionsChild DevelopmentSettore MED/38 - Pediatria Generale E SpecialisticaChild PreschoolBody SizeHumansFemaleLongitudinal StudiesChildFollow-Up Studies
researchProduct

Disease awareness in patients with COPD: measurement and extent

2018

Ilaria Baiardini,1 Paola Rogliani,2 Pierachille Santus,3 Angelo G Corsico,4 Marco Contoli,5 Nicola Scichilone,6 Fabiano Di Marco,7 Patrizia Lessi,8 Carla Scognamillo,8 Giorgia Molinengo,9 Fabio Ferri,10 Vincenzo Patella,11 Giuseppe Fiorentino,12 Mauro Carone,13 Fulvio Braido14 1Department of Biomedical Sciences, Humanitas University, Milan, Italy; 2Respiratory Unit, Department of Experimental Medicine, University of Rome &amp;ldquo;Tor Vergata&amp;rdquo;, Rome, Italy; 3Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Milan, Italy; 4Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; 5Department of Medical Sciences, University of F…

MaleHealth Knowledge Attitudes PracticeTime Factorspatient satisfactionSettore MED/10 - Malattie dell'Apparato RespiratorioDiseaseSeverity of Illness IndexPulmonary Disease Chronic Obstructive0302 clinical medicineCost of IllnessSurveys and QuestionnairesActivities of Daily Living80 and overawareness030212 general & internal medicineLungIllness BehaviorAged 80 and overPracticeCOPDHealth PolicyHealth KnowledgeGeneral MedicineMiddle AgedItalyFemalePublic HealthPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtySocio-culturaleInternational Journal of Chronic Obstructive Pulmonary DiseasePulmonary DiseaseTreatment satisfactionIllness perceptions03 medical and health sciencesNegatively associatedAwareness; COPD; Patient satisfaction; Questionnaire; Activities of Daily Living; Aged; Aged 80 and over; Cost of Illness; Dyspnea; Female; Humans; Illness Behavior; Italy; Lung; Male; Middle Aged; Patient Compliance; Patient Satisfaction; Pulmonary Disease Chronic Obstructive; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Awareness; Health Knowledge Attitudes Practice; Patient Acceptance of Health CaremedicineHumansCOPDIn patientAgedlcsh:RC705-779business.industryquestionnaireEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAwareneReproducibility of Resultslcsh:Diseases of the respiratory systemPatient Acceptance of Health Caremedicine.diseaseCOPD; awareness; patient satisfaction; questionnaireawareness; COPD; patient satisfaction; questionnaire; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational HealthClinical trialDyspnea030228 respiratory systemClinical Trial ReportAttitudesPhysical therapyPatient CompliancePatient awarenessbusiness
researchProduct

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct